Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
The FDA has approved remibrutinib (Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2026-01-05
- DOI
- https://doi.org/10.58347/tml.2026.1745b
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00